Wobenzym in therapy of rheumatoid arthritis

Guseinov N.I.

Oil-Workers Hospital, Baku, Azerbaijan

Proceedings of the VII International Congress on Immunorehabilitation “Allergy, Immunology and Global Network : Insight into the New Millennium” New York, USA, April 14 – 17, 2001
International Journal on Immunorehabilitation 2001, Vol. 3, No. 2, pp. 73-74.

By now there are no precise indication to select basic preparations while treating rheumatoid arthritis (RA). The basic treatment of RA is limited by the risk of adverse drug reactions. There are no non-toxic basic preparations for this purpose except of polyenzyme preparations.
74 patients with RA underwent ínvestigation. Group I (n=40) received Wobenzym 30 tablets daily during the first month, then 15 tablets daily for a long-term treatment. Group II (n=34) received Tauredon as basic therapy in a standard way: 1 week, 10 mg/day; 2 week, 20 mg/day, 3 week, 50 mg/day, 4 week till the 20 week 50 mg/day. In both groups, non-steroid anti-inflammatory drugs were administered additionally as basic therapy (150-200 mg/day). Both groups were comparatively equal in clinical-laboratory characteristics. The influence of basic therapy on the evolution of joint syndrome was studied in the dynamics of clinical and laboratory indicators. Our results showed that the defínite signs of RA remission appear at the end of the first month in t group 1 and in the group II at the 3-4 months. The dose of non-steroid anti-inflammatory drugs was reduced, respectively. This confirms the literature data on the basic properties of Wobenzym therapy.